Earnings Summary

Haemonetics Corp’s revenue jumped 12.77% since last year same period to $343.29Mn in the Q1 2024. On a quarterly growth basis, Haemonetics Corp has generated 2.09% jump in its revenue since last 3-months.

Haemonetics Corp’s net profit fell -30.68% since last year same period to $20.37Mn in the Q1 2024. On a quarterly growth basis, Haemonetics Corp has generated -34.81% fall in its net profits since last 3-months.

Haemonetics Corp’s net profit margin fell -38.53% since last year same period to 5.93% in the Q1 2024. On a quarterly growth basis, Haemonetics Corp has generated -36.14% fall in its net profit margins since last 3-months.

Haemonetics Corp’s price-to-earnings ratio after this Q1 2024 earnings stands at 39.99.

Haemonetics Corp’s earning per share (EPS) estimates for the current quarter stand at 1 - a 12.36% jump from last quarter’s estimates.

Haemonetics Corp’s earning per share (EPS) estimates for the current year stand at 1.

Haemonetics Corp’s earning per share (EPS) jumped 16.88% since last year same period to 0.9 in the Q1 2024. This indicates that the Haemonetics Corp has generated 16.88% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Haemonetics Corp’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Haemonetics Corp’s return on equity (ROE) stands at 0.13.